由于估值具有吸引力、BD(业务发展)与IPO活动回暖,以及密集的核心催化剂点位,生物制药板块在2026年正展现出强劲的增长潜力。尽管该行业的整体营收和盈利增长预期略低于市场平均水平,但其低风险属性与强大的管线期权价值,使其成为投资者平衡科技股配置的理想替代方案。 据追风交易台消息,花旗分析师Jarwei Fang团队6日发布研究报告,认为2025年美国生物制药板块表现不俗,成功打破了连续两年的低迷...
Source Link由于估值具有吸引力、BD(业务发展)与IPO活动回暖,以及密集的核心催化剂点位,生物制药板块在2026年正展现出强劲的增长潜力。尽管该行业的整体营收和盈利增长预期略低于市场平均水平,但其低风险属性与强大的管线期权价值,使其成为投资者平衡科技股配置的理想替代方案。 据追风交易台消息,花旗分析师Jarwei Fang团队6日发布研究报告,认为2025年美国生物制药板块表现不俗,成功打破了连续两年的低迷...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.